Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study
Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited. The objective of this study was to estimate associations between efavirenz use and depression and suicidal ideation among PLHIV in Uganda.
Rare but severe liver side-effects reported among South African patients starting efavirenz-based ART
Treatment with efavirenz has been associated with rare but severe liver complications among patients receiving antiretroviral therapy (ART) in South Africa. Writing in AIDS, investigators report three patterns of efavirenz drug-induced liver injury (DILI), the most severe of which involved necrosis with severe elevations in transaminases (ALT/AST) and jaundice. Mortality rates were high.
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.
Efavirenz has become one of the most commonly used antiretroviral agents worldwide and is a component of WHO's recommended first-line antiretroviral therapy regimen. Recently, questions have been raised about whether the dose of efavirenz could be reduced to lessen toxic effects and cost while preserving effectiveness.
The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from a study conducted in Uganda presented on Monday at the HIV Drug Therapy Glasgow conference.